212 related articles for article (PubMed ID: 24123380)
21. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
22. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
23. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.
Gondek LP; Tiu R; O'Keefe CL; Sekeres MA; Theil KS; Maciejewski JP
Blood; 2008 Feb; 111(3):1534-42. PubMed ID: 17954704
[TBL] [Abstract][Full Text] [Related]
24. Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category.
Huh J; Jung CW; Kim HJ; Kim YK; Moon JH; Sohn SK; Kim HJ; Min WS; Kim DH
Genes Chromosomes Cancer; 2013 Jan; 52(1):44-55. PubMed ID: 23023762
[TBL] [Abstract][Full Text] [Related]
25. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M
Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
[TBL] [Abstract][Full Text] [Related]
26. High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes.
O'Keefe CL; Tiu R; Gondek LP; Powers J; Theil KS; Kalaycio M; Lichtin A; Sekeres MA; Maciejewski JP
Exp Hematol; 2007 Feb; 35(2):240-51. PubMed ID: 17258073
[TBL] [Abstract][Full Text] [Related]
27. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
[TBL] [Abstract][Full Text] [Related]
28. Clinical utilization of high-resolution single nucleotide polymorphism based oligonucleotide arrays in diagnostic studies of pediatric patients with solid tumors.
Dougherty MJ; Tooke LS; Sullivan LM; Hakonarson H; Wainwright LM; Biegel JA
Cancer Genet; 2012; 205(1-2):42-54. PubMed ID: 22429597
[TBL] [Abstract][Full Text] [Related]
29. Prognostic classification of MDS is improved by the inclusion of FISH panel testing with conventional cytogenetics.
Kokate P; Dalvi R; Koppaka N; Mandava S
Cancer Genet; 2017 Oct; 216-217():120-127. PubMed ID: 29025586
[TBL] [Abstract][Full Text] [Related]
30. Refined cytogenetic IPSS-R evaluation by the use of SNP array in a cohort of 290 MDS patients.
Scarpelli I; Stalder VB; Tsilimidos G; Rapakko K; Costanza M; Blum S; Schoumans J
Genes Chromosomes Cancer; 2023 Dec; 62(12):721-731. PubMed ID: 37449676
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes.
Mohamedali A; Gäken J; Twine NA; Ingram W; Westwood N; Lea NC; Hayden J; Donaldson N; Aul C; Gattermann N; Giagounidis A; Germing U; List AF; Mufti GJ
Blood; 2007 Nov; 110(9):3365-73. PubMed ID: 17634407
[TBL] [Abstract][Full Text] [Related]
32. Cytogenomic array detects a subset of myelodysplastic syndrome with increased risk that is invisible to conventional karyotype.
Choi SM; Van Norman SB; Bixby DL; Shao L
Genes Chromosomes Cancer; 2019 Nov; 58(11):756-774. PubMed ID: 31334569
[TBL] [Abstract][Full Text] [Related]
33. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
34. [Cytogenetic profile in patients with primary myelodysplastic syndrome].
Gritsaev SV; Martynkevich IS; Petrova EV; Martynenko LS; Ivanova MP; Aksenova VIu; Tsybakova NIu; Potikhonova NA; Abdulkadyrov KM
Ter Arkh; 2013; 85(7):43-9. PubMed ID: 24137946
[TBL] [Abstract][Full Text] [Related]
35. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
[TBL] [Abstract][Full Text] [Related]
36. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
37. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome.
Mohamedali AM; Alkhatabi H; Kulasekararaj A; Shinde S; Mian S; Malik F; Smith AE; Gäken J; Mufti GJ
Blood; 2013 Jul; 122(4):567-70. PubMed ID: 23760614
[TBL] [Abstract][Full Text] [Related]
38. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS).
Mohamedali AM; Gäken J; Ahmed M; Malik F; Smith AE; Best S; Mian S; Gaymes T; Ireland R; Kulasekararaj AG; Mufti GJ
Leukemia; 2015 Sep; 29(9):1928-38. PubMed ID: 25943179
[TBL] [Abstract][Full Text] [Related]
39. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
40. Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes.
He R; Wiktor AE; Durnick DK; Kurtin PJ; Van Dyke DL; Tefferi A; Patnaik MS; Ketterling RP; Hanson CA
Am J Clin Pathol; 2016 Jul; 146(1):86-94. PubMed ID: 27353768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
